16Jul

EKF Quo-Test® supports improved medical management of diabetic retinopathy patients

EKF_1

Cardiff, UK – 16th July 2019 – EKF Diagnostics, the global in vitro diagnostics company, announces that its Quo-Test® HbA1c analyzer is successfully supporting improved medical management of patients with sight-threatening diabetic retinopathy (STDR). The effectiveness of this point of care HbA1c testing application for rapid assessment of glycaemic control in eye clinic patients has been presented at the Royal College of Ophthalmologists (RCOphth) annual congress in Glasgow. This follows the shortlisting of a study [1] undertaken by the Great Western Hospitals NHS Foundation Trust, Swindon, UK, for the 2019 RCOphth Sustainability Prize sponsored by Bausch+Lomb.

Diabetic eye disease is a leading cause of sight impairment in working age adults, and sight threatening diabetic retinopathy (STDR) patients have been found to often have poor knowledge and insight into their diabetic control. The study at the Great Western Hospital aimed to evaluate the clinical impact of measuring HbA1c in an Ophthalmology outpatient setting in patients with STDR. Using EKF’s Quo-Test to provide rapid HbA1c results from finger prick blood, the clinic concluded that POC HbA1c is a useful tool to improve patient education, as well as identify and rapidly refer those with poor diabetic control.

Shortlisted from a field of 198 abstracts accepted for presentation at the annual RCOphth College Congress, lead author Dr Sunil Mamtora, Specialty Registrar in Ophthalmology, Great Western Hospital, said, “We are delighted with the feedback that our study received, our study showed that POC HbA1c has a huge potential to improve the medical management of patients with diabetic retinopathy. There is also potential for monitoring in clinical trials to further evaluate links between glycaemic control and new diabetic eye disease therapies, such as intravitreal injection treatment for diabetic macular oedema.”

Dr Mamtora, explained how EKF’s Quo-Test POC HbA1c is a very useful tool now used routinely in Great Western Hospital eye clinics, “As it is a validated solution listed by NHS England, we chose to use Quo-Test to obtain a fast HbA1c result within our clinic. Following the success of our study, we now use it routinely to rapidly assess patients with poor diabetic control, or those who have not had HbA1c measured within the last 6 months, and we are considering referral to a diabetes specialist. If POC HbA1c is over 64mmol/mol then the diabetes clinic allows us to refer directly to them based on this validated POC result.”

Further benefits of receiving fast turnaround and lab accurate HbA1c results using Quo-Test were also noted by the study. These included the ability to educate patients with poorly controlled diabetes at the point of care and eliminate the need for follow up communication or visits. Being able to test, triage and refer directly to the diabetes clinic from Ophthalmology outpatients makes POC HbA1c an ideal screening tool to rapidly identify STDR patients who would benefit from intensified diabetes medical management.

Of the 198 abstracts accepted for the 2019 Royal College of Ophthalmologists Sustainability Prize sponsored by Bausch+Lomb, only 61 (31%) were considered to fulfil one of the seven steps to sustainability. These are interventions which prevent disease or morbidity, improve productivity, streamline pathways, reduce procurement costs or carbon dioxide emissions, educate and empower patients or healthcare professionals and facilitate more patient centred care. All were assessed on the overall quality of the project but also their contribution to hitting the triple bottom line of reduced financial, social and environmental costs (people, profits and planet). This strong field was narrowed down to a final 20 candidates for the prize, including the POC HbA1c testing at the Great Western Hospital eye clinic. 

The study poster can be viewed at: www.ekfdiagnostics.com/res/A0_hb1c.pdf. For more information on Quo-Test® see: www.ekfdiagnostics.com  

Reference:

  1. Mamtora, S. et al. (2019). Improving the medical management of patients with sight-threatening diabetic retinopathy. Poster presentation at RCOphth annual College Congress (May 2019).

 

- ENDS -

 

Link for this press release on EKF’s website: www.ekfdiagnostics.com/ekf-quo-test-in-diabetic-retinopathy-patients.html

Related

A Valuable New Information Resource for Faecal Immunochemical Testing (FIT) for Bowel Cancer Detection

www.faecal-immunochemical-test.co.uk is a dedicated new website, developed by Alpha Laboratories Ltd...

Read More >

New Partnership for Biological Sample Transport Solutions

Specialist Laboratory and Diagnostics supply company Alpha Laboratories Ltd. (Eastleigh, UK) is deli...

Read More >

SpeeDx and Thermo Fisher Scientific announce strategic partnership for FDA clearance of molecular diagnostic test

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed an agreement ...

Read More >

Cytox awarded new Innovate UK funding for Alzheimer’s disease testing

8 March 2018: Oxford & Manchester, UK. Cytox, an emerging precision medicine leader providing geneti...

Read More >

Reduce Your Costs for Biological Sample Transport

How do you package your send-away pathology samples? Are you spending too much time and money on pac...

Read More >

EKF Diagnostics publishes ‘Diabetes and HbA1c testing’ guide

Cardiff, UK – 17th July 2017 – EKF Diagnostics, the global in vitro diagnostics company, has publi...

Read More >